ALNYLAM PHARMACEUTICALS, INC.·4

Aug 9, 4:09 PM ET

KEATING LAURIE 4

4 · ALNYLAM PHARMACEUTICALS, INC. · Filed Aug 9, 2021

Insider Transaction Report

Form 4
Period: 2021-08-05
KEATING LAURIE
SVP,GC & Secretary
Transactions
  • Exercise/Conversion

    Common Stock

    2021-08-05$88.95/sh+7,876$700,57013,008 total
  • Sale

    Common Stock

    2021-08-05$188.95/sh10,000$1,889,5005,132 total
  • Exercise/Conversion

    Performance Stock Option 2015 (right to buy)

    2021-08-052,12411,876 total
    Exercise: $88.95From: 2019-08-06Exp: 2025-12-18Common Stock (2,124 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2021-08-057,8761,124 total
    Exercise: $88.95Exp: 2025-12-18Common Stock (7,876 underlying)
  • Exercise/Conversion

    Common Stock

    2021-08-05$88.95/sh+2,124$188,93015,132 total
Holdings
  • Common Stock

    (indirect: by Managed Account)
    434
Footnotes (3)
  • [F1]All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.
  • [F2]Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
  • [F3]The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT